A Non-Randomized Open Label, Adaptive, Parallel Group, Human Positron Emission Tomography (PET) Study to Assess Occupancy of Brain alpha5-Containing GABAA Receptors of Ro7017773 Using [11C] Ro15-4513 Following Single Oral Doses in Healthy Participants
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2019
Price : $35 *
At a glance
- Drugs RO-7017773 (Primary) ; Benzodiazepines
- Indications Autistic disorder
- Focus Pharmacokinetics
- Sponsors Roche
- 08 Oct 2018 Status changed from recruiting to completed.
- 05 Oct 2018 Planned End Date changed from 5 Oct 2018 to 30 Nov 2018.
- 05 Oct 2018 Planned primary completion date changed from 8 Sep 2018 to 30 Nov 2018.